Clyde Launches New Contractility Service – CellOPTIQ®-X

Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma clients. CellOPTIQ®-X represents a revolution in contractility assays, offering:

  • Early detection of contractility toxicities
  • Higher throughput, cost-effective solution
  • Reduction in animal requirements
  • Accurate prediction of the human response
  • Reduction in later stage attrition

 

Heart cell contractility is a sensitive indicator of toxic effects of drugs. Issues are commonly highlighted later on in drug development than would be ideal (in vivo/ex vivo animal testing). CellOPTIQ® -X has been designed to efficiently and cost effectively test for human contractility issues earlier, reducing animal usage and preventing later stage attrition.

Clyde’s CellOPTIQ® system captures and analyses up to 200 high resolution images per second, elucidating differential inotropic effects on contractile proteins. Developed on a 96-well format using iPS human cardiomyocytes, the assay has been shown to be predictive of the clinical setting accurately measuring the effects of the following inotropes;

  • Negatives: Nifedipine, Itraconazole, Blebbistatin, Atenolol, Thapsigargin
  • Positives: Isoproterenol, Pimobendan, Amrinone, BayK8644, Digoxin

 

For more information contact info@clydebio.com

###

Download press release here.